Vitamin D and Osteoporosis Prevention in Elderly African American Women

NCT ID: NCT01153568

Last Updated: 2018-10-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 260 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-08-31
• Study Completion Date: 2016-10-31

Brief Summary

Vitamin D is a hormone that is produced when sunlight is absorbed by the skin. Vitamin D insufficiency has been recognized as a problem in areas where sun exposure is limited, especially in the wintertime. In addition, the more pigmented the skin is, the less capable it is of utilizing sunlight to make vitamin D. Vitamin D plays an important role in helping the body absorb calcium and in building strong bones. It has also been shown to improve muscle function in the elderly. As we get older, our vitamin D levels in the blood go down and this may increase the risk for falls and fractures. If we can improve vitamin D status as we age, we may be able to improve muscle strength and decrease the risk of falls and fractures.

Detailed Description

The long-term goal of this project is to develop strategies for the prevention of osteoporotic fractures in African Americans. Most intervention studies have excluded African Americans because of the erroneous belief that osteoporosis is not a major health problem in this population. In fact, the incidence rate of hip fracture in blacks is 50% of the rate in whites. Since longevity is increasing in the black population, osteoporotic fractures will become an even greater problem for this ethnic minority in the future. Furthermore, morbidity and mortality from osteoporotic fractures is greater in blacks. The elderly require higher intake of vitamin D to prevent bone loss resulting from secondary hyperparathyroidism. Calcium with sufficient vitamin D supplementation may decrease fractures in elderly white populations as a result of reduction in bone loss and falls (improved physical performance). The only fracture intervention study to include African Americans-the Women's Health Initiative-used an inadequate dose of vitamin D (400 IU), a dose unlikely to achieve the vitamin D status proposed by U.S. experts: serum 25 hydroxyvitamin D [25(OH)D] concentration above 75 nmol/L. No calcium/vitamin D intervention studies on fall prevention or physical performance have included African Americans.

As a result of increased skin pigmentation, blacks synthesize less vitamin D from sun exposure. As a result, serum 25(OH)D levels are often in the "insufficient" range. This is accompanied by secondary hyperparathyroidism, but adult blacks have a relative skeletal resistance to PTH, so that they have lower bone turnover. They also have more efficient renal conservation of calcium starting in childhood. Addition of vitamin D3 to a calcium-sufficient African American postmenopausal population does not prevent bone loss. The calcium/vitamin D requirements of black adults may be lower than white adults through midlife. However, the elderly require more vitamin D to produce the higher 25(OH)D levels required to overcome the hyperparathyroidism associated with aging. The skeleton of elderly African Americans appears to be susceptible to the increasing parathyroid hormone levels of old age. Bone loss accelerates and bone turnover markers increase in elderly African Americans just as in whites. The specific aims of this project are to determine if dietary supplementation with calcium/vitamin D will safely reduce bone loss and bone turnover and improve physical performance in elderly African Americans. We will enroll 250 African American women in a four-year vitamin D3 intervention trial where serum 25(OH)D will be maintained at an optimum level above 75 nmol/L. Adequate calcium intake will be ensured. Functional markers of vitamin D including bone density, serum PTH, and bone turnover will be measured. The NIH Conference on Vitamin D and Health in the 21st Century, September 5-6, 2007 concluded that research in this population is a high priority.

Conditions

Determine Effect of Vitamin D on Bone Health in Elderly African American Women

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

placebo

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: OTHER

placebo tablets

Vitamin D 3

Vitamin D3 will be available in doses of 60, 90, 120, and 150 µg

Group Type: EXPERIMENTAL

Vitamin D 3

Intervention Type: DIETARY_SUPPLEMENT

Patients will bew given a single capsule to take once daily

Interventions

Vitamin D 3

Patients will bew given a single capsule to take once daily

Intervention Type: DIETARY_SUPPLEMENT

placebo

placebo tablets

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Ambulatory women older than 60 years of age. Self declared as African Americans.

2. 20 nmol/L < serum 25(OH)D level < 65 nmol/L.

3. Willingness to take study drug and participate for four years in the trial.

4. Willingness to refrain from the use of self-administered supplements during the trial.

Exclusion Criteria

1. Serum 25(OH)D levels ≤ 20 nmol/L or ≥ 65 nmol/L.

2. BMD total hip below - 2.5 standard deviation (using NHANES III adult young white men and women as the point of reference) or history of osteoporotic fracture.

3. Moderate to severe fracture in one or more vertebrae by Instant Vertebral Assessment on DXA.

4. Treatment with HRT, SERMS, calcitonin, PTH, androgens, bisphosphonates, phosphate or anabolic steroids during 6 months prior to entry.

5. Use of systemic corticosteroids (oral or IV) within the last year at an average dose of greater than 5 mg per day of oral prednisone or equivalent for a period of three months or more prior to screening.

6. Hypercalcemia (serum calcium > 10.6 mg (dl) or history of primary hyperparathyroidism.

7. History of chronic liver disease, chronic renal insufficiency, Parkinson's, metabolic bone disease, hematologic tumors, rheumatologic disease requiring steroids, malabsorption or new diagnosis or active treat-ment of cancer 12 months prior to inclusion.

8. Use of medications that influence bone metabolism (e.g. anticonvulsants).

9. Significant deviation from normal in either: history, physical examination or laboratory tests as evaluated by the Principle Investigator. Participants with a history of hypercalciuria, nephrolithiasis and active sarcoidosis will also be excluded.

10. Participation in another investigational trial 30 days prior to screening.

11. Spinal disease that affects interpretation of bone densitometry like scoliosis with a Cobb angle greater than 15o, history of surgery at lumbosacral spine.

12. Bilateral hip replacement.

13. Currently smoking more than 10 cigarettes daily.

14. Body width on DXA > 25 cm.

15. Patients who are deemed unsafe to perform muscular function testing as evaluated by the investigator.

---------- Study participants should live close to the study site, as this study requires multiple visits over a four year period.

• Minimum Eligible Age: 60 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute on Aging (NIA)

NIH

Sponsor Role: collaborator

Winthrop University Hospital

OTHER

Sponsor Role: lead

Responsible Party

John F. Aloia, MD

Chief Academic Officer

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

John F. Aloia, MD

Role: PRINCIPAL_INVESTIGATOR

Winthrop University Hospital

Locations

Winthrop University Hospital

Mineola, New York, United States

Countries

United States

References

Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006 Jul;84(1):18-28. doi: 10.1093/ajcn/84.1.18.

Reference Type: BACKGROUND

PMID: 16825677 (View on PubMed)

Aloia JF, Vaswani A, Yeh JK, Flaster E. Risk for osteoporosis in black women. Calcif Tissue Int. 1996 Dec;59(6):415-23. doi: 10.1007/BF00369203.

Reference Type: BACKGROUND

PMID: 8939764 (View on PubMed)

Cauley JA, Lui LY, Stone KL, Hillier TA, Zmuda JM, Hochberg M, Beck TJ, Ensrud KE. Longitudinal study of changes in hip bone mineral density in Caucasian and African-American women. J Am Geriatr Soc. 2005 Feb;53(2):183-9. doi: 10.1111/j.1532-5415.2005.53101.x.

Reference Type: BACKGROUND

PMID: 15673339 (View on PubMed)

Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007 Aug 25;370(9588):657-66. doi: 10.1016/S0140-6736(07)61342-7.

Reference Type: BACKGROUND

PMID: 17720017 (View on PubMed)

Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab. 2003 Jan;88(1):185-91. doi: 10.1210/jc.2002-021064.

Reference Type: BACKGROUND

PMID: 12519850 (View on PubMed)

Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005 May 11;293(18):2257-64. doi: 10.1001/jama.293.18.2257.

Reference Type: BACKGROUND

PMID: 15886381 (View on PubMed)

Latham NK, Anderson CS, Lee A, Bennett DA, Moseley A, Cameron ID; Fitness Collaborative Group. A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: the Frailty Interventions Trial in Elderly Subjects (FITNESS). J Am Geriatr Soc. 2003 Mar;51(3):291-9. doi: 10.1046/j.1532-5415.2003.51101.x.

Reference Type: BACKGROUND

PMID: 12588571 (View on PubMed)

MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest. 1985 Oct;76(4):1536-8. doi: 10.1172/JCI112134.

Reference Type: BACKGROUND

PMID: 2997282 (View on PubMed)

Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005 Jul;16(7):713-6. doi: 10.1007/s00198-005-1867-7. Epub 2005 Mar 18.

Reference Type: BACKGROUND

PMID: 15776217 (View on PubMed)

Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath JJ, Norman AW, Scragg R, Whiting SJ, Willett WC, Zittermann A. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr. 2007 Mar;85(3):649-50. doi: 10.1093/ajcn/85.3.649. No abstract available.

Reference Type: BACKGROUND

PMID: 17344484 (View on PubMed)

Visser M, Deeg DJ, Puts MT, Seidell JC, Lips P. Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr. 2006 Sep;84(3):616-22; quiz 671-2. doi: 10.1093/ajcn/84.3.616.

Reference Type: BACKGROUND

PMID: 16960177 (View on PubMed)

Dhesi JK, Bearne LM, Moniz C, Hurley MV, Jackson SH, Swift CG, Allain TJ. Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status. J Bone Miner Res. 2002 May;17(5):891-7. doi: 10.1359/jbmr.2002.17.5.891.

Reference Type: BACKGROUND

PMID: 12009020 (View on PubMed)

Bischoff HA, Stahelin HB, Dick W, Akos R, Knecht M, Salis C, Nebiker M, Theiler R, Pfeifer M, Begerow B, Lew RA, Conzelmann M. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res. 2003 Feb;18(2):343-51. doi: 10.1359/jbmr.2003.18.2.343.

Reference Type: BACKGROUND

PMID: 12568412 (View on PubMed)

Wicherts IS, van Schoor NM, Boeke AJ, Visser M, Deeg DJ, Smit J, Knol DL, Lips P. Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab. 2007 Jun;92(6):2058-65. doi: 10.1210/jc.2006-1525. Epub 2007 Mar 6.

Reference Type: BACKGROUND

PMID: 17341569 (View on PubMed)

Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB. Effect of Vitamin D on falls: a meta-analysis. JAMA. 2004 Apr 28;291(16):1999-2006. doi: 10.1001/jama.291.16.1999.

Reference Type: BACKGROUND

PMID: 15113819 (View on PubMed)

Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, Santora AC, Sherwood LM. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res. 2005 Feb;20(2):185-94. doi: 10.1359/JBMR.041007. Epub 2004 Oct 18.

Reference Type: RESULT

PMID: 15647811 (View on PubMed)

Aloia JF, Islam S, Mikhail M. Vitamin D and Acute Respiratory Infections-The PODA Trial. Open Forum Infect Dis. 2019 Sep 4;6(9):ofz228. doi: 10.1093/ofid/ofz228. eCollection 2019 Sep.

Reference Type: DERIVED

PMID: 31660391 (View on PubMed)

Aloia JF, Mikhail M, Fazzari M, Islam S, Ragolia L, Guralnik J. Physical Performance and Vitamin D in Elderly Black Women-The PODA Randomized Clinical Trial. J Clin Endocrinol Metab. 2019 May 1;104(5):1441-1448. doi: 10.1210/jc.2018-01418.

Reference Type: DERIVED

PMID: 30496578 (View on PubMed)

Aloia J, Fazzari M, Islam S, Mikhail M, Shieh A, Katumuluwa S, Dhaliwal R, Stolberg A, Usera G, Ragolia L. Vitamin D Supplementation in Elderly Black Women Does Not Prevent Bone Loss: A Randomized Controlled Trial. J Bone Miner Res. 2018 Nov;33(11):1916-1922. doi: 10.1002/jbmr.3521. Epub 2018 Jul 19.

Reference Type: DERIVED

PMID: 29905969 (View on PubMed)

Related Links

http://www.nof.org

National Osteoporosis Foundation

http://www.niams.nih.gov

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Other Identifiers

R01AG032440

Identifier Type: NIH

Identifier Source: secondary_id

View Link

08032

Identifier Type: -

Identifier Source: org_study_id